Stocks · News reference
Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $20
Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $18 to $20.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical
Carlsmed, Inc. filed a patent infringement lawsuit against DeGen Medical, Inc. in the U.S. District Court for the District of South Carolina, alleging infringement of eight patents related to AI-enabled personalized spine surgery implants, methods, and systems. Carlsmed is seeking injunctive relief and damages.
Carlsmed Announces Promotion Of Jeff Bertolini To COO, Effective Immediately
8-K filing — CARLSMED, INC. (CARL)
Filed: 2026-09-08 AccNo: 0001794546-26-000018 Size: 181 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits